The impact of targeted therapies in the treatment landscape of liver cancer

0 Views

07/13/23

Weijia Fang, Zhejiang University, Hangzhou, China, comments on the utility of targeted therapies in treating liver cancer. The first targeted therapy approved for liver cancer was sorafenib and several other clinical trials such as the CheckMate040 study (NCT01658878) has demonstrated the potential of combining checkpoint inhibitors with other targeted therapies. Dr Fang additionally talks on novel biomarkers of interest such as tumor mutational burden (TMB) as well as novel approaches including epithelial cell adhesion molecule (EpCAM) in chimeric antigen receptor (CAR)-T cell therapy. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.